Longeveron Inc.

Miami, FL

UEI
PYXXAC2HV5T3
CAGE
7B7W6
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1951 NW 7th Ave #520, Miami, FL 33136, USA
Website
longeveron.com
Founded
2014
Employees
11-50
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A phase 2B clinical trial to study the efficacy of longeveron mesenchymal stem cells (lmscs) to treat aging frailty R44AG062015 National Institute on Aging (NIH) $4,240,853
A randomized, blinded, placebo-controlled clinical trial to evaluate longeveron mesenchymal stem cell (lmsc) therapy… R42AG054322 National Institute on Aging (NIH) $1,051,486

Grant subawards

Prime recipient Prime award Amount Awarded
ANN & Robert H Lurie Childrens Hospital Of Chicago Dr. Joshua Hare is a Co-PI of this project and is the Co-Founder and Chief Science Officer of Longeveron LLC (Longeveron). Dr. Hare will work very closely… UH3HL148318 $373,303

Quick answers

Is Longeveron Inc. registered in SAM.gov?

Yes. Longeveron Inc.'s SAM.gov registration is active through January 13, 2027.

What is Longeveron Inc.'s most recent federal award?

Longeveron Inc.'s most recent federal grant award is A phase 2B clinical trial to study the efficacy of longeveron mesenchymal stem cells (lmscs) to treat aging frailty (R44AG062015), from National Institute on Aging (NIH), on September 30, 2018.

On GovTribe

See Longeveron Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login